Past depression tied to worse breast cancer survival odds : foxnews

As it stated in foxnews

Past depression tied to worse breast cancer survival odds

Past depression tied to worse breast cancer survival odds

Women with a history of depression may have lower survival odds with breast cancer than patients without past mental health problems, research in Denmark suggests.In the study of more than 45,000 women with early-stage breast malignancies, 13 percent of patients previously treated with antidepressants died within five years of their cancer diagnosis, compared with 11 percent of women who hadn't ever taken medication for depression."We did not find that women with depression were diagnosed at later stages," said lead study author Dr. Nis Palm Suppli of the Danish Cancer Society Research Center in Copenhagen.Instead, women with depression may be less likely to start or continue recommended treatments based on individual factors including a patient's age, tumor size, the type of cancer and how far it has spread in the body, Suppli added by email.


let alone cancerresearchuk

Black African women almost twice as likely to be diagnosed with late stage breast cancer compared to white women

Black African women almost twice as likely to be diagnosed with late stage breast cancer compared to white women

Black African women are nearly twice as likely to be diagnosed with late stage breast cancer as white women in England according to new analysis* from Cancer Research UK and Public Health England released.While there are still gaps, this information provides a useful insight into which ethnic groups are more likely to be diagnosed with late stage cancer - Dr Jodie MoffatTwenty five per cent of Black African women and 22 per cent of Black Caribbean women diagnosed with breast cancer are picked up at stage three and four.This compares to thirteen per cent of white British women.This is the first time data on more specific ethnic groups and their stage at diagnosis from across England has been routinely released, helping to build a clearer picture of who is diagnosed at an early or late stage.


by the same token on ucla

Drug combination therapy for estrogen-receptor–positive breast cancer passes critical step for worldwide approval

Drug combination therapy for estrogen-receptor–positive breast cancer passes critical step for worldwide approval

Building on earlier clinical trials, UCLA researchers have confirmed that the "breakthrough" drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone.The study, published online today in the New England Journal of Medicine, is the phase 3 study following phase 1 and phase 2 clinical trials that led to U.S. Food and Drug Administration approval of palbociclib in early 2015.Palbociclib was also approved in Europe for the first time earlier in November based on these results.In 2013, after women in a clinical study led by UCLA researchers showed a dramatic improvement, the FDA granted palbociclib "breakthrough therapy" status, allowing it to be fast-tracked for approval.